The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia

American Journal of Pathology

Volumn 157, Issue 3, 2000, Pages 737-745

  Agoff, S Nicholas ^a   Brentnall, Teresa A ^a   Crispin, David A ^a   Taylor, Shari L ^a   Raaka, Stuart ^a   Haggitt, Rodger C ^a   Reed, Michael W ^b   Afonina, Irina A ^b   Rabinovitch, Peter S ^a   Stevens, Allyn C ^a   Feng, Ziding ^c   Bronner, Mary P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Epoch Pharmaceuticals   (United States)

^c Fred Hutchinson Cancer Center and University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; TAQ POLYMERASE;

ADENOMATOUS POLYP; ARTICLE; CHEMOPROPHYLAXIS; COLON RESECTION; COLON TUMOR; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

EID: 0034492927     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64587-7     Document Type: Article

References (46)

1. Chemopreventive effects of NSAIDs against colorectal cancer: Regulation of apoptosis and mitosis by COX-1 and COX-2
2. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology
3. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
4. Elevated cyclooxygenase-2 levels in Min mouse adenomas
5. Expression of cyclooxygenase-1 and 2 in human colorectal cancer
6. Treatment of colonic and rectal adenomas with Sulindac in FAP
7. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study
8. Aspirin use and reduced risk of fatal colon cancer
9. Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the nonsteroidal anti-inflammatory drug Piroxicam
10. Suppression of intestinal polyposis in APC knockout mice by inhibition of COX-2
11. Precancer and cancer in inflammatory bowel disease
12. Risk factors for development of colorectal cancer in inflammatory bowel disease
13. Carcinoma and ulcerative colitis
14. Molecular genetic profiles of colitis-associated neoplasms
15. Loss of heterozygosity and microsatellite instability in non-neoplastic mucosa from patients with chronic ulcerative colitis
16. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis
17. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model
18. C-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma
19. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms
20. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis
21. Microsatellite instability in non-neoplastic mucosa from patients with chronic ulcerative colitis
22. Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele
23. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical application
24. Microwave based antigenic unmasking: A revolutionary new technique for routine immunohistochemistry
25. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis
26. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis
27. Detection of specific PCR reaction product by utilizing the 5′ to 3′ exonuclease activity of Thermus aquaticus DNA polymerase
28. 3′-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures
29. Cloning the difference between two complex genomes
30. Expressed genes in interleukin-4 treated B cells identified by cDNA representational difference analysis
31. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease
32. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease
33. Unequivocal demonstration that malondialdehyde is a mutagen
34. Mutagenicity of malondialdehyde, a decomposition product of peroxidized polyunsaturated fatty acids
35. The activity of the peroxide-metabolizing system in human colon carcinoma
36. Lipid peroxidation and prostaglandins in colorectal cancer
37. Genetic alteration and oxidative metabolism in sporadic colorectal tumors from a Spanish community
38. Oxidative damage and transforming growth factor beta-1 expression in pretumoral and tumoral lesions of human intestine
39. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
40. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
41. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
42. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and non-ulcerogenic
43. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach
44. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease
45. Association between analgesic use and inflammatory bowel disease flares: A retrospective cohort study
46. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2